Tuesday, December 20, 2016
CureDuchenne Ventures Backs TRiNDS
Newport Beach-based CureDuchenne Ventures, a company which specifically funds startups working on Duchenne muscular dystrophy, said on Monday that it has made an investment in TRiNDS, a new contract research organization. The company said TRiNDS was formed out of the Cooperative International Neuromuscular Research Group (CINRG) academic consortium. Size of the funding was not announced. TRiNDS--short for Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS)--says it is a specialized contract research organization (CRO) for neuromuscular diseases, with a focus on clinical operations, data management, biostatistics, and study measurements.